11Dec/13

Idelalisib/Rituximab Combo Improves Survival in Late-Stage CLL – Cancer Network

Monoclonal Anti-CD20 Antibodies

Idelalisib/Rituximab Combo Improves Survival in Late-Stage CLL
Cancer Network
The progression-free survival (PFS) rate at 24 weeks was 93% for patients treated with idelalisib plus rituximab compared with 46% for patients treated with rituximab alone. The median PFS of the combination arm has not yet been reached. The median PFS …
Idelalisib plus rituximab extended survival in previously treated CLLHealio
Gilead’s Pipeline EncouragesYahoo News

all 6 news articles »
11Dec/13

Idelalisib plus rituximab extended survival in previously treated CLL – Healio

Monoclonal Anti-CD20 Antibodies

Idelalisib plus rituximab extended survival in previously treated CLL
Healio
NEW ORLEANS — The addition of idelalisib to rituximab significantly extended survival in heavily pretreated patients with relapsed chronic lymphocytic leukemia, according to phase 3 study results presented at the ASH Annual Meeting and Exposition.
Idelalisib/Rituximab Combo Improves Survival in Late-Stage CLLCancer Network
Gileads Pipeline EncouragesZacks.com

all 3 news articles »
10Dec/13

Latest Data Further Support Ibrutinib's Efficacy in CLL – OncLive

Monoclonal Anti-CD20 Antibodies

OncLive

Latest Data Further Support Ibrutinib’s Efficacy in CLL
OncLive
Combining ibrutinib with the chemoimmunotherapy regimen of bendamustine (Treanda) plus rituximab (Rituxan) demonstrated a high level of activity and was tolerable for patients with relapsed or refractory CLL.1 Presenting the final results of the 30 …
Pharmacyclics Announces Data Presentations for Ibrutinib in B-Cell MalignanciesMarketWatch

all 34 news articles »
10Dec/13

Celgene Corporation : Studies Evaluating REVLIMID® (Lenalidomide) in … – 4-traders (press release)

Monoclonal Anti-CD20 Antibodies

Celgene Corporation : Studies Evaluating REVLIMID® (Lenalidomide) in …
4-traders (press release)
In the first study, Dr. Nishitha M. Reddy evaluated whether maintenance treatment with lenalidomide plus rituximab would result in a clinically significant reduction in relapse rates when compared with lenalidomide alone. DLBCL patients with an …

and more »
10Dec/13

Studies Evaluating REVLIMID® (Lenalidomide) in Lymphoma Presented at ASH – Business Wire (press release)

Monoclonal Anti-CD20 Antibodies

Studies Evaluating REVLIMID® (Lenalidomide) in Lymphoma Presented at ASH
Business Wire (press release)
In the first study, Dr. Nishitha M. Reddy evaluated whether maintenance treatment with lenalidomide plus rituximab would result in a clinically significant reduction in relapse rates when compared with lenalidomide alone. DLBCL patients with an …

and more »
10Dec/13

Positive Data on Infinity Pharma Candidate – Zacks.com

Monoclonal Anti-CD20 Antibodies

Positive Data on Infinity Pharma Candidate
Zacks.com
The study will evaluate the safety and efficacy of IPI-145 in iNHL patients whose disease is refractory to radioimmunotherapy or to both Roche/Biogen Idec Inc.’s (RHHBY)/(BIIB – Analyst Report) Rituxan (rituximab) and chemotherapy and who have …
Infinity Reports Updated Phase 1 Data of IPI-145 in Indolent Non-Hodgkin …Business Wire (press release)
Infinity Reports Preclinical Data at ASH Annual Meeting in Diffuse Large B …MarketWatch

all 25 news articles »